Imbio
Curated by SignalImage-based clinical decision support
Overview
Imbio is a medical imaging company that develops clinical decision-support solutions using big data and medical image analysis. The company's current offerings are focused on 3D visualization and automated analysis of respiratory system images derived from CT scans. These include CE marked Functional Lung Density Analysis (fLDA) tests (a fully-automated image analysis system that provides a complete mapping of normal lung, air trapping, and areas of persistent low density in a combined image to help visualize the components of COPD), and LDA for Inspiration Analysis for Lung Screening and basic COPD assessment (test to identify and quantify emphysema), and Lung Texture Analysis using High Resolution CT images (for visualization, detection and quantification of lung fibrosis). The company has also developed investigational/research tools for airway analysis (analysis of airway remodelling, a characteristic feature of many lung diseases), computer-aided nodule assessment and risk yield (also called CANARY, this is a non-invasive imaging technique licensed from the Mayo Clinic, to risk stratify adenocarcinoma) and RV/LV analysis to predict short-term mortality and adverse clinical events in patients with acute pulmonary embolism.
Key facts
- Founded
- 2005
- Headquarters
- Minneapolis, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Contact
- Sign up to view